1885 related articles for article (PubMed ID: 23872058)
1. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
2. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs.
Mimoto F; Kadono S; Katada H; Igawa T; Kamikawa T; Hattori K
Mol Immunol; 2014 Mar; 58(1):132-8. PubMed ID: 24334029
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
[TBL] [Abstract][Full Text] [Related]
4. IgG2m4, an engineered antibody isotype with reduced Fc function.
An Z; Forrest G; Moore R; Cukan M; Haytko P; Huang L; Vitelli S; Zhao JZ; Lu P; Hua J; Gibson CR; Harvey BR; Montgomery D; Zaller D; Wang F; Strohl W
MAbs; 2009; 1(6):572-9. PubMed ID: 20073128
[TBL] [Abstract][Full Text] [Related]
5. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
[TBL] [Abstract][Full Text] [Related]
6. IgG2 Fc structure and the dynamic features of the IgG CH2-CH3 interface.
Teplyakov A; Zhao Y; Malia TJ; Obmolova G; Gilliland GL
Mol Immunol; 2013 Nov; 56(1-2):131-9. PubMed ID: 23628091
[TBL] [Abstract][Full Text] [Related]
7. Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions.
Grevys A; Bern M; Foss S; Bratlie DB; Moen A; Gunnarsen KS; Aase A; Michaelsen TE; Sandlie I; Andersen JT
J Immunol; 2015 Jun; 194(11):5497-508. PubMed ID: 25904551
[TBL] [Abstract][Full Text] [Related]
8. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
[TBL] [Abstract][Full Text] [Related]
9. Global conformational changes in IgG-Fc upon mutation of the FcRn-binding site are not associated with altered antibody-dependent effector functions.
Burvenich IJG; Farrugia W; Liu Z; Makris D; King D; Gloria B; Perani A; Allan LC; Scott AM; Ramsland PA
Biochem J; 2018 Jul; 475(13):2179-2190. PubMed ID: 29794155
[TBL] [Abstract][Full Text] [Related]
10. Structural analysis of Fc/FcγR complexes: a blueprint for antibody design.
Caaveiro JM; Kiyoshi M; Tsumoto K
Immunol Rev; 2015 Nov; 268(1):201-21. PubMed ID: 26497522
[TBL] [Abstract][Full Text] [Related]
11. Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees.
Newman R; Hariharan K; Reff M; Anderson DR; Braslawsky G; Santoro D; Hanna N; Bugelski PJ; Brigham-Burke M; Crysler C; Gagnon RC; Dal Monte P; Doyle ML; Hensley PC; Reddy MP; Sweet RW; Truneh A
Clin Immunol; 2001 Feb; 98(2):164-74. PubMed ID: 11161972
[TBL] [Abstract][Full Text] [Related]
12. Full-length recombinant antibodies from
Rashid MH
MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
[TBL] [Abstract][Full Text] [Related]
13. Correlation between CD16a binding and immuno effector functionality of an antigen specific immunoglobulin Fc fragment (Fcab).
Kainer M; Antes B; Wiederkum S; Wozniak-Knopp G; Bauer A; Rüker F; Woisetschläger M
Arch Biochem Biophys; 2012 Oct; 526(2):154-8. PubMed ID: 22634259
[TBL] [Abstract][Full Text] [Related]
14. Structural consequences of aglycosylated IgG Fc variants evolved for FcγRI binding.
Ju MS; Na JH; Yu YG; Kim JY; Jeong C; Jung ST
Mol Immunol; 2015 Oct; 67(2 Pt B):350-6. PubMed ID: 26153451
[TBL] [Abstract][Full Text] [Related]
15. An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIa
Kang TH; Lee CH; Delidakis G; Jung J; Richard-Le Goff O; Lee J; Kim JE; Charab W; Bruhns P; Georgiou G
Front Immunol; 2019; 10():562. PubMed ID: 30984171
[TBL] [Abstract][Full Text] [Related]
16. Engineering IgG1 Fc Domains That Activate the Complement System.
Lee CH; Delidakis G
Methods Mol Biol; 2022; 2421():187-200. PubMed ID: 34870820
[TBL] [Abstract][Full Text] [Related]
17. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
[TBL] [Abstract][Full Text] [Related]
18. Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions.
Schlothauer T; Herter S; Koller CF; Grau-Richards S; Steinhart V; Spick C; Kubbies M; Klein C; Umaña P; Mössner E
Protein Eng Des Sel; 2016 Oct; 29(10):457-466. PubMed ID: 27578889
[TBL] [Abstract][Full Text] [Related]
19. Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcγRIIIa.
Ahmed AA; Keremane SR; Vielmetter J; Bjorkman PJ
J Struct Biol; 2016 Apr; 194(1):78-89. PubMed ID: 26850169
[TBL] [Abstract][Full Text] [Related]
20. Avidity confers FcγR binding and immune effector function to aglycosylated immunoglobulin G1.
Nesspor TC; Raju TS; Chin CN; Vafa O; Brezski RJ
J Mol Recognit; 2012 Mar; 25(3):147-54. PubMed ID: 22407978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
